Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) Meeting Abstract


Authors: Cella, D.; Escudier, B.; Rini, B. I.; Chen, C.; Bhattacharyya, H.; Tarazi, J. C.; Rosbrook, B.; Kim, S.; Motzer, R. J.
Abstract Title: Patient-reported outcomes (PROs) in a phase III AXIS trial of axitinib versus sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880300546
DOI: 10.1200/jco.2011.29.15_suppl.4504
PROVIDER: wos
Notes: Meeting Abstract: 4504 -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Robert Motzer
    1243 Motzer